Swedish biotech company Immuneed AB and Danish biotech company ImmuMap ApS have entered into a collaboration agreement, the signing of which was announced today.
The agreement combines our two companies’ scientific expertise, specialized laboratory platforms and unique methodological know-how, enabling us to offer even better tailored solutions for our customers. ImmuMap’s long-term mode-of-action cellular immune analyses form an ideal complement to Immuneed’s strong focus on immediate immune-related responses in the human circulatory system after drug administration.
Through this collaboration, we will simplify our customers’ decision processes by giving them access to preclinically relevant human-based data that supports more comprehensive characterization of modern biotherapeutics.
About Immuneed AB
Immuneed AB, founded in 2014, provides services to biotech and pharmaceutical companies. We address important questions related to drug safety and immunology, thereby cutting costs and adding value to drug development projects. Our goal is to provide truly meaningful insights that help our customers enter clinical trials prepared. Immuneed’s services are enabled by our proprietary platform based on circulating, fresh human blood. The platform links preclinical data to clinical reality ™– in the only commercially available system of its kind. www.immuneed.com
About Immumap Services ApS
ImmuMap, founded in 2016, offers customized flow cytometry assays and enzyme- or fluorescence-linked immunospot (ELISpot/fluorospot) for immune monitoring and consulting. Staffed by PhD-level scientists and co-founded by immune technology key opinion leader Sine Reker Hadrup, our business has extensive scientific and methodological expertise at its core.
We have developed several platforms for high-throughput screening and profiling of antigen-specific T cells, including the Deep Profiling assay, providing multilayered characterization of specific T cell populations, and the dCODE™ platform, used for parallel identification and enumeration of 50–1031 different T cell specificities. www.immumap.com